46.3 Acute Urinary Retention & Incontinence Evaluation

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

46.3 Acute Urinary Retention & Incontinence Evaluation

Key Takeaways Explain This Topic AI

Acute Urinary Retention (AUR) is the sudden, agonizing inability to voluntarily pass urine despite a painfully distended bladder with a Post-Void Residual (PVR) >300 to 500 mL; initial decompression requires prompt urethral catheterization with a 14-16 Fr Foley catheter or a curved Coudé catheter to negotiate an enlarged median prostatic lobe.

Following bladder decompression, patients must be strictly monitored for pathologic Post-Obstructive Diuresis (defined as urine output >200 mL/hr for >=2 consecutive hours); if accompanied by hemodynamic instability or electrolyte derangements, initiate intravenous replacement using 0.45% saline at 0.5 times (50%) the hourly urine volume to avoid perpetuating an iatrogenic diuresis.

For AUR precipitated by BPH, initiate an alpha-1 adrenergic antagonist (Tamsulosin 0.4 mg daily or Alfuzosin) immediately on the day of catheterization and maintain decompression for 3 to 7 days prior to conducting a Trial Without Catheter (TWOC), which achieves a 60% to 70% success rate compared to <30% without an alpha-blocker.

Long-term BPH disease modification requires 5-alpha-reductase inhibitors (Finasteride 5 mg daily or Dutasteride), which shrink prostatic volume by 20% to 30% and reduce long-term rates of AUR and surgery in glands >30 to 40 mL; 5-ARIs suppress serum PSA by 50% after 6 months, requiring clinicians to DOUBLE the measured PSA value when screening for prostate cancer.

Urinary incontinence classification dictates targeted management: Stress incontinence (urethral hypermobility) responds to pelvic floor muscle training (Kegels) and midurethral slings; Urgency incontinence (detrusor overactivity) is treated with bladder training, antimuscarinics, or beta-3 agonists (Mirabegron/Vibegron, which avoid anticholinergic cognitive impairment); and Overflow incontinence (elevated PVR >200-300 mL) mandates relieving obstruction and strictly avoiding antimuscarinic agents.

Last updated: September 2026

Etiology & Pathophysiology of Acute Urinary Retention (AUR)

Acute urinary retention (AUR) is defined as the sudden, painful inability to voluntarily void urine, resulting in acute, tense overdistension of the urinary bladder. AUR is the most common urologic emergency in adult men, with an annual incidence of approximately 3 cases per 1,000 person-years, rising dramatically in men aged >=70 years.

Mechanistic Classification

The pathophysiologic mechanisms underlying acute urinary retention fall into three broad categories:

Outflow Obstruction (Mechanical Obstruction) :

Benign Prostatic Hyperplasia (BPH) : The single leading cause of AUR (>70% of cases), resulting from nodular adenomatous hyperplasia of the transition zone surrounding the proximal urethra.

Prostate adenocarcinoma, urethral stricture disease, bladder calculi, meatal stenosis, severe phimosis, and pelvic or retroperitoneal malignancies.

Severe Constipation and Fecal Impaction : Massive hard stool in the rectal vault mechanically compresses the posterior bladder neck and urethra, while stimulating rectal mechanoreceptors that reflexively inhibit detrusor contraction.

Neurogenic & Detrusor Contractility Failure :

Acute spinal cord compression, Cauda Equina Syndrome (characterized by saddle anesthesia, lax anal sphincter tone, and bilateral lower extremity weakness; AUR with overflow incontinence carries >90% sensitivity for CES).

Diabetic autonomic neuropathy (diabetic cystopathy causing sensory denervation and atonic detrusor failure), acute stroke, tabes dorsalis, and multiple sclerosis.

Pharmacologic Precipitation :

Drug-induced urinary retention is responsible for up to 30% of all acute presentations in older adults. HIGH-RISK DRUG CLASSES PRECIPITATING URINARY RETENTION

• Medication Class Specific Common Agents Mechanism Inducing Retention
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Anticholinergics / Diphenhydramine, Hydroxyzine, Block muscarinic M3 receptors on the
• First-Gen Antihistamines Chlorpheniramine, Meclizine detrusor muscle, abolishing bladder

contractile force.

Bladder Antispasmodics Oxybutynin, Tolterodine, Potent competitive M2/M3 receptor

Solifenacin, Darifenacin antagonism; suppresses detrusor activity.

Tricyclic Amitriptyline, Nortriptyline, Potent anticholinergic antagonism

Antidepressants (TCAs) Imipramine, Doxepin combined with central sedation.

• Sympathomimetics / Pseudoephedrine, Ephedrine, Stimulate alpha-1 adrenergic receptors
• Oral Decongestants Phenylephrine at the bladder neck and prostatic

capsule, markedly increasing outflow resistance.

Opioid Analgesics Morphine, Oxycodone, Hydrocodone, Inhibit central sacral micturition pathways,

Fentanyl, Hydromorphone decrease bladder sensation, and relax detrusor.

Anesthetic Agents / Spinal anesthesia, epidural, Bladder sensory stunning, hyperhydration,

Postoperative State high-dose IV sedatives and pain-mediated sympathetic tone.

• ═════════════════════════════════════════════════════════════════════════════════════════════
• Clinical Presentation & Emergency Bladder Decompression
• Clinical Presentation

Symptoms : Agonizing, severe lower abdominal and suprapubic pain, accompanied by an intense, relentless urge to urinate but complete inability to void. Patients appear acutely distressed, restless, diaphoretic, and hypertensive from profound autonomic sympathetic stimulation.

Physical Examination :

Palpation and percussion of the lower abdomen reveals a tense, smooth, tender, globe-like suprapubic mass arising out of the pelvis, which is dull to percussion.

Digital rectal examination evaluates prostate volume, contour, symmetry, and tenderness, while confirming the presence or absence of fecal impaction.

Focused neurological examination must assess bilateral lower extremity motor strength, patellar and Achilles reflexes, perineal sensation ( S2-S5 dermatomes ), and resting/voluntary anal sphincter tone to rule out cauda equina compression.

Diagnostic Confirmation :

Bedside bladder ultrasonography or formal post-void residual (PVR) measurement: A documented urine volume >300 to 500 mL in a patient who cannot void establishes the diagnosis of AUR.

Catheter Decompression Technique & The Coudé Tip Catheter

Immediate bladder decompression is the primary therapeutic priority. Decompression relieves excruciating suffering, terminates sympathetic overdrive, and prevents permanent myogenic detrusor damage.

Standard Urethral Catheterization :

Cleanse the glans penis and instill 10 to 20 mL of sterile 2% lidocaine jelly into the urethra using a prefilled syringe, holding the meatus closed for 5 to 10 minutes to achieve topical anesthesia and gentle hydrodistension.

Insert a standard 14 to 16 French soft silicone or latex Foley catheter with gentle continuous traction on the penis at a 90° angle toward the ceiling (straightening the anterior urethra).

The Difficult Catheterization & The Coudé Catheter :

If the catheter meets firm, rubbery resistance at 15 to 20 cm from the meatus, the catheter has reached the prostatic urethra and bladder neck .

CLINICAL MANDATE : Never use forceful pressure against resistance! Forcing a standard straight-tip catheter risks creating a traumatic mucosal false passage, deep urethral laceration, massive hemorrhage, or bladder neck perforation.

The Coudé Tip Catheter :

A specialized catheter with a firm, angled, upward-curved (elbowed) beak.

The curved tip is designed specifically to ride anteriorly over an enlarged, hypertrophied median prostatic lobe or elevated bladder neck.

Proper Technique : Insert the Coudé catheter with the curved tip pointing strictly upward toward the ceiling / patient's umbilicus (12 o'clock position) . Most Coudé catheters have a raised indicator ridge on the drainage funnel indicating the direction of the curved beak.

Failed Transurethral Catheterization :

If two attempts with a Coudé catheter fail, do not make repeated blind attempts. Immediately consult urology for flexible cystoscopy-guided wire placement or emergent percutaneous suprapubic cystostomy .

Post-Obstructive Diuresis (POD): Monitoring & Management

Following rapid decompression of severe or long-standing urinary tract obstruction, patients can develop a dangerous, life-threatening polyuric syndrome known as Post-Obstructive Diuresis (POD) .

Pathophysiological Mechanism

Post-obstructive diuresis is defined as a sustained urine output of >200 mL/hour for >=2 consecutive hours , or >3,000 to 4,000 mL in 24 hours following relief of obstruction. The mechanisms include:

Osmotic Diuresis : Rapid excretion of high concentrations of accumulated urea, creatinine, and unabsorbed osmoles that were retained during the obstructive episode, dragging water osmotically into the tubular lumen.

Loss of Medullary Hypertonicity : Long-standing elevated retrograde intrarenal pressures wash out the hypertonic medullary solute gradient (medullary washout), impairing the countercurrent multiplier mechanism.

Tubular Unresponsiveness : Ischemic injury to renal medullary collecting ducts produces transient tubular insensitivity to antidiuretic hormone (nephrogenic diabetes insipidus-like state) and downregulates sodium-potassium ATPase pumps, provoking profound natriuresis.

Clinical Monitoring Protocol

Not all post-catheterization polyuria is pathological. In many patients, polyuria is simply a physiologic diuresis eliminating excess extracellular fluid retained during renal compromise. Clinicians must differentiate physiologic volume shedding from pathologic salt-wasting diuresis: POST-OBSTRUCTIVE DIURESIS PROTOCOL

• Clinical Parameter Monitoring Frequency Intervention Threshold
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Urine Volume Strict hourly measurement via > 200 mL/hr for 2 consecutive hours

graduated urometer bag activates close monitoring protocol.

Hemodynamics & Vitals Hourly blood pressure, pulse, Drop in SBP, tachycardia, or orthostasis

and postural signs indicates intravascular volume depletion.

Electrolytes & Renal Serum BUN, Creatinine, Na, K, Check every 6 to 12 hours; monitor for

Function Panels Bicarbonate, Mg, Phosphorus severe hypokalemia, hyponatremia, uremia.

Fluid Balance & Weight Daily weights; strict 24-hour Guides net fluid balance and reveals

intake and output totals unrecognized fluid contraction.

• ═════════════════════════════════════════════════════════════════════════════════════════════
• Fluid Replacement Strategy: The 50% Rule

Alert, Hemodynamically Stable Patients : If the patient is awake, alert, possesses normal thirst mechanisms, maintains stable vital signs, and has access to oral fluids, routine intravenous fluid replacement is NOT necessary . Over-treating with IV fluids is the single most common clinical error: administering rapid IV fluids perpetuates a continuous, iatrogenic polyuric state by continuously infusing volume that the kidneys must clear!

Hemodynamically Unstable or Pathologic Salt-Wasting Diuresis :

Indicated if the patient exhibits postural hypotension, tachycardia, altered mental status, severe electrolyte depletion (hypokalemia, hyponatremia), or cannot drink.

The 0.5x Replacement Rule : Administer intravenous 0.45% normal saline (half-normal saline, with potassium chloride supplementation as indicated by serum levels) replacing 0.5 times (50%) of the preceding hour's urine output : IV Infusion Rate (mL/hr) = 0.5 × Urine Output in Preceding Hour (mL) \text{IV Infusion Rate (mL/hr)} = 0.5 \times \text{Urine Output in Preceding Hour (mL)} IV Infusion Rate (mL/hr) = 0.5 × Urine Output in Preceding Hour (mL)

This replacement rate maintains adequate effective circulating arterial volume without driving an endless cycle of iatrogenic volume-overload polyuria.

Outpatient BPH Management After Retention: The TWOC Protocol

When acute urinary retention is precipitated by benign prostatic hyperplasia, the clinical objective is to transition the patient from indwelling catheter dependence to successful spontaneous voiding.

The Trial Without Catheter (TWOC) Protocol

Immediate Pharmacotherapy : Initiate an oral selective alpha-1 adrenergic receptor antagonist (e.g., Tamsulosin 0.4 mg PO daily or Alfuzosin 10 mg PO daily) on the very day of catheter placement.

Duration of Catheterization : Maintain continuous indwelling catheter drainage for 3 to 7 days . A minimum of 3 days allows time for the overdistended, micro-teared detrusor muscle to recover baseline contractile tone, for acute intraprostatic edema to subside, and for the alpha-blocker to achieve steady-state therapeutic levels.

Conducting the TWOC :

The patient presents to the clinic early in the morning.

Remove the Foley catheter and encourage normal oral hydration.

Observe the patient for spontaneous voiding over the subsequent 4 to 6 hours.

Following spontaneous urination, measure the post-void residual (PVR) via ultrasound.

TWOC Outcomes :

Successful TWOC : Patient voids spontaneously with adequate volumes and a PVR <150 to 200 mL without abdominal discomfort. The patient continues the alpha-blocker long-term with routine outpatient follow-up.

Failed TWOC : Patient is unable to void within 4 to 6 hours, experiences severe painful distension, or demonstrates a persistently elevated PVR (>200 to 300 mL). Re-insert a Foley catheter immediately and refer to urology for definitive surgical consideration.

The Evidence : Landmark randomized clinical trials prove that initiating an alpha-blocker prior to TWOC doubles the rate of successful voiding (60% to 70% success with alpha-blocker vs 25% to 35% with placebo) and significantly reduces early recurrence of AUR.

Long-Term Pharmacotherapy of Benign Prostatic Hyperplasia (BPH)

Benign prostatic hyperplasia is characterized by progressive non-malignant adenomatous proliferation of the prostatic glandular and stromal elements, causing bladder outlet obstruction. COMPARATIVE PHARMACOLOGY OF BPH MEDICATIONS

• Drug Class & Agents Mechanism of Action Clinical Impact & Onset Adverse Effects & Pearls
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Alpha-1 Adrenergic Block alpha-1A receptors in • RAPID onset (within 3-7 days) • Dizziness, headache
• Antagonists prostate stroma, capsule, • Improves IPSS by 4-6 points • Orthostatic hypotension
• Tamsulosin 0.4 mg and bladder neck; relaxes • Increases Qmax by 2-3 mL/s • Retrograde ejaculation
• Alfuzosin 10 mg smooth muscle to decrease • Does NOT shrink prostate • Intraoperative Floppy
• Silodosin 8 mg dynamic outflow resistance. • Does NOT prevent AUR/surgery Iris Syndrome (IFIS)

• 5-Alpha-Reductase Inhibit conversion of • SLOW onset (requires 6-12 mo) • Decreased libido, ED
• Inhibitors (5-ARIs) testosterone to DHT; induces • SHRINKS prostate by 20-30% • Ejaculatory dysfunction
• Finasteride 5 mg epithelial apoptosis. • Halts disease progression • Gynecomastia
• Dutasteride 0.5 mg Targeted for enlarged glands • Reduces AUR risk by ~57% • SUPPRESSES SERUM PSA
• (volume > 30-40 mL). • Reduces surgery risk by ~55% BY 50% (Must double PSA)

• Combination Therapy Synergistic dynamic relaxation • Superior to either monotherapy• Summation of individual
• Tamsulosin PLUS combined with progressive • Validated by MTOPS & CombAT adverse effect profiles
• Dutasteride/Finasteride anatomic volume reduction. trials for high-risk BPH

• PDE-5 Inhibitors Increase intracellular cGMP; • Rapid relief of mild-moderate • Headache, flushing, dyspepsia
• Tadalafil 5 mg daily relaxes detrusor, prostate, LUTS with concurrent ED • Contraindicated with nitrates
• and pelvic vasculature. • No effect on prostate size
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Clinical Pearls: Alpha-Blockers & IFIS

Intraoperative Floppy Iris Syndrome (IFIS) :

Alpha-1 adrenergic receptors are located in the iris dilator muscle. Systemic alpha-1 blockers (particularly tamsulosin, due to its high alpha-1A selectivity) cause permanent or long-lasting loss of iris muscle tone.

During cataract extraction surgery, patients taking (or who have previously taken) alpha-blockers can develop a classic triad: billowing of a flaccid iris stroma, progressive intraoperative pupillary miosis, and prolapse of the iris toward the phacoemulsification incision.

Clinical Mandate : Primary care physicians must ask patients about upcoming cataract surgery prior to starting alpha-blockers, and advise patients to explicitly inform their ophthalmologist so that mechanical iris retractors or intraoperative intracameral phenylephrine can be utilized.

Clinical Pearls: 5-ARIs & The PSA-Doubling Rule

Important

THE 5-ALPHA-REDUCTASE INHIBITOR PSA-DOUBLING MANDATE Treatment with a 5-alpha-reductase inhibitor (Finasteride 5 mg daily or Dutasteride 0.5 mg daily) suppresses serum Prostate-Specific Antigen (PSA) by approximately 50% after 6 months of continuous therapy .

To evaluate serum PSA accurately for prostate cancer screening in a patient who has taken a 5-ARI for >=6 months, the clinician MUST MULTIPLY THE MEASURED SERUM PSA VALUE BY 2 (DOUBLE THE VALUE) to compare it to historical baselines and normal population thresholds. Any confirmed rise in serum PSA while a patient is compliant on a 5-ARI is abnormal and warrants immediate urologic referral for prostate cancer evaluation.

Diagnostic Evaluation & Classification of Urinary Incontinence

Urinary incontinence is the involuntary loss of urine, representing a major clinical and quality-of-life issue affecting over 50% of community-dwelling older women and up to 15% of older men.

Initial Evaluation & Reversible Causes: The DIAPPERS Mnemonic

Before diagnosing primary bladder dysfunction, primary care physicians must screen for transient, reversible precipitants using the validated DIAPPERS framework:

• D — Delirium / Acute confusional state
• I — Infection (Symptomatic urinary tract infection)
• A — Atrophic vaginitis / Atrophic urethritis (hypoestrogenism)
• P — Pharmaceuticals (Diuretics, anticholinergics, alpha-blockers, sedatives)
• P — Psychological disorders (Severe depression)

E — Excessive urine output (Uncontrolled diabetes mellitus with glucosuria, hypercalcemia, congestive heart failure with dependent edema)

• R — Restricted mobility (Severe osteoarthritis, contractures, environmental barriers)
• S — Stool impaction / Severe constipation SYSTEMATIC CLASSIFICATION OF URINARY INCONTINENCE

• Incontinence Type Pathophysiologic Mechanism Clinical Hallmark Post-Void Residual
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Stress Urinary Urethral hypermobility (pelvic floor Involuntary leakage with NORMAL
• Incontinence (SUI) laxity) OR intrinsic sphincter coughing, sneezing, laughing, (PVR < 50 mL)

deficiency. Intravesical pressure jumping, or lifting. No urge.

exceeds urethral closure pressure.

• Urgency Urinary Detrusor muscle overactivity Sudden, compelling urge to NORMAL
• Incontinence (UUI) / (involuntary detrusor contractions urinate followed immediately by (PVR < 50-100 mL)

Overactive Bladder during filling phase). uncontrolled large-volume leakage.

• Overflow Urinary Impaired detrusor contractility Constant or intermittent ELEVATED
• Incontinence (neurogenic / myogenic) OR severe involuntary dribbling, weak (PVR > 200-300 mL)

bladder outlet obstruction. stream, incomplete emptying.

• Functional Intact bladder mechanics; physical, Inability to reach toilet in NORMAL
• Incontinence cognitive, or environmental barriers time due to arthritis, dementia,

prevent timely toilet access. sedation, or physical restraints.

• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Evidence-Based Management by Incontinence Subtype
• 1. Stress Urinary Incontinence (SUI)

First-Line Conservative Therapy : Structured Pelvic Floor Muscle Training (PFMT / Kegel exercises) , supervised by a physical therapist. Prescribe 3 sets of 10 to 15 sustained contractions (held for 6 to 8 seconds) daily for at least 12 weeks . Biofeedback and vaginal weighted cones enhance compliance.

Second-Line Mechanical Devices : Vaginal pessaries (e.g., incontinence dish or ring with knob) or disposable urethral inserts support the bladder neck and compress the urethra during intra-abdominal pressure spikes.

Surgical Gold Standard : Midurethral synthetic sling (tension-free vaginal tape [TVT] or transobturator tape [TOT]) or bladder neck suspension (Burch colposuspension). In men with post-prostatectomy stress incontinence, an artificial urinary sphincter (AUS) is the gold standard.

2. Urgency Urinary Incontinence (UUI) / Overactive Bladder (OAB)

First-Line Behavioral Interventions : Bladder training (scheduled timed voiding with progressive interval expansion by 15-30 minutes), urge suppression techniques (deep diaphragmatic breathing, pelvic floor distraction contractions), caffeine, artificial sweetener, and alcohol reduction, and fluid moderation.

Second-Line Pharmacotherapy :

Antimuscarinics / Anticholinergics (Oxybutynin, Tolterodine, Solifenacin, Fesoterodine, Darifenacin):

Competitively antagonize muscarinic M2 and M3 receptors in the detrusor muscle, abolishing involuntary spasms.

Adverse Effects : Dry mouth, severe constipation, blurred vision, dyspepsia, and urinary retention.

Geriatric Caution (Beers Criteria) : Central anticholinergic burden causes cognitive decline, memory impairment, delirium, and is epidemiologically associated with an increased long-term risk of incident dementia . Avoid in older adults and patients with cognitive vulnerability.

Beta-3 Adrenergic Receptor Agonists (Mirabegron 25 to 50 mg daily, Vibegron 75 mg daily) :

Stimulate beta-3 adrenergic receptors on the detrusor muscle, activating adenylyl cyclase to produce smooth muscle relaxation and increase functional bladder capacity during filling without blocking muscarinic receptors.

Major Clinical Advantage : Free of anticholinergic central nervous system adverse effects; safe for cognitive function in older adults.

Precautions : Mirabegron can increase systolic blood pressure (average increase 1 to 3 mmHg); contraindicated in patients with severe uncontrolled hypertension (SBP >=180 mmHg or DBP >=110 mmHg) . Vibegron has minimal blood pressure effects.

Third-Line Refractory Therapies : Intravesical OnabotulinumtoxinA (Botox) injections into the detrusor, sacral neuromodulation (InterStim), or percutaneous tibial nerve stimulation (PTNS).

3. Overflow Incontinence

Mandatory First Step : Decompress the distended bladder via urethral catheterization or clean intermittent self-catheterization (CIC).

Treat the Underlying Cause : Initiate alpha-blockers or schedule surgical resection (TURP) for prostatic outlet obstruction; surgically correct pelvic organ prolapse; discontinue offending anticholinergics, opioids, or tricyclic antidepressants.

CONTRAINDICATION : Antimuscarinic drugs and beta-3 agonists are strictly contraindicated in overflow incontinence because suppressing residual detrusor contractility will precipitate complete urinary retention.

4. Functional Incontinence

Optimize environmental mobility: Provide bedside commodes, urinal bottles, nightlights, remove throw rugs, install raised toilet seats and grab bars.

Implement scheduled, prompted voiding protocols every 2 to 3 hours with caregiver assistance; review and deprescribe sedating psychotropics and diuretics.

Loading diagram... Clinical Algorithm for Acute Urinary Retention and Incontinence Evaluation